Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Dose-Ranging, Observer-Blind, Four-Arm, Placebo-Controlled Study of VBI-1501 to Assess the Safety and Immunogenicity of Three Different Dosages of VBI-1501

Next Previous
Trial Profile

A Phase II Dose-Ranging, Observer-Blind, Four-Arm, Placebo-Controlled Study of VBI-1501 to Assess the Safety and Immunogenicity of Three Different Dosages of VBI-1501

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 1501A (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors VBI Vaccines

Most Recent Events

  • 08 Jan 2019 New trial record
  • 20 Dec 2018 According to a VBI Vaccines media release, Following discussions with Health Canada, toxicology studies are underway, the results of which are required prior to the start of the clinical study, which is expected to initiate enrollment around the end of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top